• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Atai Life Sciences N.V. (NQ: ATAI )

    1.845 -0.125 (-6.35%)
    Streaming Delayed Price Updated: 12:09 PM EDT, Apr 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 502,334
    Open 1.960
    Bid (Size) 1.840 (28)
    Ask (Size) 1.850 (37)
    Prev. Close 1.970
    Today's Range 1.845 - 1.960
    52wk Range 1.025 - 2.850
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
    From atai Life Sciences
    Via GlobeNewswire
    Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
    A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
    Via Talk Markets

    Performance

    YTD
    +9.17%
    +9.17%
    1 Month
    +11.14%
    +11.14%
    3 Month
    +0.82%
    +0.82%
    6 Month
    +50.00%
    +50.00%
    1 Year
    -6.35%
    -6.35%

    More News

    Read More
    Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
    Via Benzinga
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    Recap: ATAI Life Sciences Q4 Earnings
    Via Benzinga
    atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
    From atai Life Sciences
    Via GlobeNewswire
    The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
    Via Talk Markets
    Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Exposures Glyphosate
    March Recap: Largest Psychedelic Drug Stocks Up Another 5%
    Via Talk Markets
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
    Via Benzinga
    Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
    Via Benzinga
    ATAI Stock Earnings: ATAI Life Sciences Beats EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
    From atai Life Sciences
    Via GlobeNewswire
    atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
    From atai Life Sciences
    Via GlobeNewswire
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    The Next Great Biotech Boom Has Arrived
    Via FinancialNewsMedia
    Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
    Via Benzinga
    Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
    Via Talk Markets
    Exposures Product Safety
    Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
    Via Benzinga
    atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
    From atai Life Sciences
    Via GlobeNewswire
    Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
    Via Talk Markets
    atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
    From atai Life Sciences
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.